

JEREMY M. DEUTSCH, M.D.

818 N Emporia Ste 403
Wichita, KS 67214

Office Phone: (316) 262-4467
Office Fax: (316) 262-0706

CURRICULUM VITAE

PERSONAL DATA

Medical Licensure: Iowa
Kansas

Board Certification: Internal Medicine (October 2010)
Board Certification: Oncology (January 2014)
Board Certification: Hematology (January 2014)

EDUCATION

Undergraduate
Bachelor of Sciences in Electrical Engineering Aug 1998 – Dec 2002
Kansas State University, Manhattan, KS

Graduate
Doctor of Medicine Aug 2003 – May 2007
University of Kansas School of Medicine, Kansas City, KS

Postgraduate
Internal Medicine Residency Jul 2007 – Jun 2010
University of Kansas School of Medicine – Wichita, Wichita, KS

Hematology & Oncology Fellowship Jul 2010 – Jun 2013
University of Iowa, Iowa City, IA

EMPLOYMENT

Medical Director, Hospice Aug 2008 – Jun 2010
Harry Hynes Memorial Hospice, Wichita, KS

Staff Physician, Immediate Care Aug 2008 – Jun 2010
Wichita Clinic, Wichita, KS

Staff Physician, Emergency Medicine June 2011 – Jun 2013
VA Medical Center, Iowa City, IA

Staff Oncologist/Hematologist July 2013 – Present
Cancer Center of Kansas, Wichita, KS

PROFESSIONAL INVOLVEMENT

<i>American College of Physicians</i>	Jul 2007 - Present
<i>American Society of Clinical Oncology</i>	Aug 2010 - Present
<i>American Society of Hematology</i>	Aug 2010 - Present

COMMUNITY SERVICE

Victory in the Valley – Board of Directors <i>Wichita, KS</i>	2018 - Present
--	----------------

CURRENT RESEARCH ACTIVITIES

Review of clinical characteristics of GIST with rare primary sites
Phase I Trial of Decitabine and Siltuximab utilizing IL-6 in the treatment of metastatic melanoma
Primary Angiosarcoma of the bone marrow
Gemcitabine as first-line therapy for metastatic angiosarcoma
Use of FLT-PET imaging concurrently for immunotherapy for metastatic melanoma

PUBLICATIONS

1. Deutsch JM, El-Osta H, Reddy P: Acquired Factor VIII inhibitors: case reports of paclitaxel and penicillin-induced entities. *Blood Coagulation and Fibrinolysis.* 2009; 20(8): 719-721.
2. Abu Hejleh, DeYoung BR, Deutsch JM, Engelman E, Zimmerman MB, Halfdanarson TR, Berg D, Parekh KR, Iannetoni MD, Bhatia S, Clamon G: Relationship of HER-2 Overexpression to Brain Metastasis in Esophageal Cancer Patients. *World J Gastrointest Oncol.* 2012 May 15;4(5):103-8.
3. Deutsch JM, Milhem MM, Neghandi A, Sudershan B: Case Report: Sequential Molecularly Targeted Combination Therapies in a Patient with Progressive Metastatic Synovial Sarcoma After Chemotherapy. *Clin Sarcoma Res.* Publication Pending.
4. Deutsch JM, Abu Hejleh T, Clamon G: Brain Metastasis from Esophageal Cancer in the Presence of HER-2 Overexpression. In *Methods of Cancer Diagnosis, Therapy, and Prognosis: Tumors of the Central Nervous System.* Springer 2012. Publication Pending.
5. Xia C, Leon-Ferre R, Laux D, Deutsch JM, Smith B, Frees M, Milhem M. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide). *Cancer Chemother Pharmacol.* (2014) 74:691-697.
6. Deutsch JM, Milhem MM. Imatinib dosing: when, how much, and how long? *Curr Clin Pharmacol.* 2015;10(4):311-20.
7. Reddy PS, Rahal AK, Kallail KJ, Moore DF, Truong PV, Mattar BI, Cannon MW, Nabbout NH, Page SJ, Truong QV, Dakhil C, Deutsch JM, Dakhil SR: The Application of Next-Generation Sequencing in the Community Clinical Oncology Setting. *J Clin Oncol.* 34, 2016 (suppl; abstr e23145).

8. Al-Obaidi A, Parker N, Choucair K, Alderson J, Deutsch JM. (May 13, 2020) A Case of Acute Heart Failure Following Immunotherapy for Metastatic Lung Cancer. *Cureus* 12(5): e8093. doi:10.7759/cureus.8093
9. Al-Obaidi A, Parker N, Choucair K, Alderson J, Deutsch JM. (June 29, 2020) A Case of Acute Heart Failure Following Immunotherapy for Metastatic Lung Cancer. *Pub Med*. doi:10.7759

SELECETED PRESENTATIONS

Xia C, Laux DE, **Deutsch JM**, Frees M, Smith B, Hohl RJ, Milhem MM. “A phase I/II study to evaluate the ability of decitabine and panobinostat to improve temozolomide chemosensitivity in metastatic melanoma.” ASCO Annual Meeting 2012, Chicago, IL.

Deutsch JM. Cancer, Chemotherapy, and Weight: Dose Selection. University of Iowa HOBMT Grand Rounds 2012. Iowa City, IA.

Deutsch JM, Neghandi A, Bhatia S, Milhem MM. “Sequential Molecularly Targeted Combination Therapy in a Patient with Progressive Metastatic Synovial Sarcoma After Chemotherapy.” Connective Tissue Oncology Society International Meeting, 2011, Chicago, IL.

Halwani A, Abu Hejleh T, **Deutsch JM**, Engelman E, Swift J, Harmaneh I, Smith B, Milhem MM. “A Pilot Study Targeting Angiogenesis Using Bevacizumab combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas.” Connective Tissue Oncology Society International Meeting, 2011, Chicago, IL.

Deutsch JM, Mattar B. “War in the Endothelium: Concurrent Bleeding and Clotting.” American College of Physicians Regional Meeting, 2009, Wichita, KS.

Deutsch JM, Reddy P. “Penicillin-Induced Acquired Hemophilia A.” American College of Physicians National Meeting, 2009, Philadelphia, PA.

Deutsch JM. “Erythrocytosis: Diagnosis and Management.” University of Kansas School of Medicine Grand Rounds, 2009, Wichita, KS.

Deutsch JM, Reddy P. “Penicillin-Induced Acquired Hemophilia A.” American College of Physicians Regional Meeting, 2008, Kansas City, KS.

Deutsch JM. “DVT Prophylaxis: The Punter of Medical Management.” University of Kansas School of Medicine Grand Rounds, 2008, Wichita, KS.

Deutsch JM. “Efficacy and Safety of Erythropoietin Alfa in Critically Ill Patients.” University of Kansas School of Medicine Grand Rounds, 2008, Wichita, KS.

Deutsch JM, Schulz TK. “Thromboprophylaxis in the ICU setting.” Wesley Regional Medical Center Quality Improvement Forum, 2009, Wichita, KS.

Deutsch JM, Peppone LJ, Mustian KM, Padula GD, Kamen CS, Guido JJ, Asare M, Kleckner I, Peoples AR, Usuki K, Cole S, Janelins MC. “Omega-3 Supplementation versus Omega-6 Supplementation for Fatigue among Breast Cancer Survivors: A URCC NCORP RCT.” Abstract #168732, submitted at ASCO Annual Meeting, June 3-7, 2016, Chicago, IL.

Deutsch JM, et al. “A Retrospective Analysis Comparing Efficacy of Filgastrim-sndz Versus Filgastrim for Autologous, Peripheral Stem Cell Mobilization in Patients With Multiple Myeloma and Lymphoma.” Abstract #225533, submitted at ASCO Annual Mtg, 1-5 May 2018

SELECTED HONORS AND AWARDS

Jeremy Deutsch, MD

CV – page 5

Platinum Certificate of Excellence National Cancer Institute Community Oncology Research Program	2017
Chief Fellow Hematology, Oncology & Blood and Marrow Transplantation, University of Iowa	2012 - 2013
Dean's Award for Clinical Teaching University of Kansas School of Medicine	2010
St. Luke's Award (Outstanding Resident in all specialties) Via Christi Regional Hospital	2010
Outstanding PGY-2 Internal Medicine University of Kansas School of Medicine	2009
Alpha Omega Alpha	2006 – present
P. Raghavan Award (Outstanding Senior Medical Student in clinical performance) University of Kansas School of Medicine	2007
W. Smith Award (Outstanding Senior Medical Student in academic performance) University of Kansas School of Medicine	2007
R. Morton Award (Outstanding Senior Medical Student in internal medicine) University of Kansas School of Medicine	2007
AMA Foundation Scholar	2006
Lose & Chont Medical Scholarships University of Kansas School of Medicine	2004 – 2006
Diploma, Cum Laude Kansas State University	2002
Order of St. Patrick Kansas State University Engineering	2002
Mortar Board Senior Honor Society Kansas State University	2001

Updated: 05/15/2020